BIIB098: MRI and relapse
results from the phase 3 EVOLVE - MS - 1 study in patients with relapsing and remitting multiple sclerosis were presented at the 70th annual meeting of the American Academy of Neurology (AAN).
The Finnish drug maker on Sunday presented
results from phase I trial of a prostate cancer treatment, saying according the data it «has been well tolerated, with no significant treatment - related adverse events.»
Detailed 48 - week
results from a Phase 3 study evaluating the efficacy and safety of switching from a regimen containing abacavir, dolutegravir and lamivudine (600 / 50/300 mg)(ABC / DTG / 3TC) to Biktarvy, a once - daily single tablet regimen, in virologically suppressed adults with HIV.
«Based on
the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»
We look forward to
the results from the phase III trial with interest.»
He says
results from phase II and III trials on these new therapies designed to stall the disease are slated to come out within the year.
These statistically significant and clinically meaningful improvements in overall response and survival rates
resulted from a phase Ib / II clinical study performed at the HonorHealth Research Institute, a partnership of HonorHealth and TGen.
An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard - to - treat cases, according to interim
results from the Phase II / III STORM - C - 1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the International Liver Conference in Paris.
The first - of - its - kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new
results from a phase I trial to be presented at the AACR Annual Meeting 2015 on April 19.
Last week, at the Psychedelic Science 2017 conference in Oakland, California, researchers presented unpublished
results from phase II trials involving a total of 107 people diagnosed with PTSD.
Afferent Pharmaceuticals today announced publication of
results from a Phase 2 clinical trial demonstrating that the company's novel drug candidate, AF - 219, reduced daytime cough frequency by 75 % compared to placebo in patients with treatment - refractory chronic cough.
Results from a phase III trial with another antibody that targets β amyloid — solanezumab, developed by Eli Lilly — should be announced later this year.
The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to
results from a phase II clinical study.
Early
results from a phase I, first in - human study indicate that a potential new class of drugs, RNA interference (RNAi) drugs, can be safely administered in humans, according to a researcher who presented data on the safety and preliminary efficacy of TKM - 080301 at the AACR Annual Meeting 2013, held in Washington, D.C., April 6 - 10.
CRI:
The results from your phase I study that were published last year were impressive and got a lot of media attention.
An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with
results from a phase I trial showing that, among 236 patients with various types of cancer, the treatment shrank tumors in 28 percent of melanoma patients, 30 percent of patients with kidney cancer, and 18 percent of patients with advanced non-small cell lung cancer.
5a: Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney G, Koller M, Ness DK, Griffith S, Grundman M, Soto J, Ostrowitzki S, Boess F, Martin - Facklam M, Quinn J, Isaacson S, Jennings D, Omidvar O, Ellenbogen A.
Results From a Phase 1b multiple ascending - dose study of PRX002, an anti — alpha - synuclein monoclonal antibody, in patients with Parkinson's disease [abstract].
Results from a phase 1 study of nusinersen (ISIS - SMNRx) in children with spinal muscular atrophy.
5: Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney GG, Koller M, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin - Facklam M, Quinn JF, Isaacson SH, Jennings D, Omidvar O, Ellenbogen A.
Results from a Phase 1b multiple ascending - dose study of PRX002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease.
Clinical Breast Cancer 2013, Final
Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2 - Negative Breast Cancers
Robert Motzer, M.D., of Memorial Sloan Kettering Cancer Center, presented
results from a phase 2 trial of nivolumab in renal cell carcinoma (RCC), commonly known as kidney cancer.
Reykjavik, ICELAND, October 19, 2004 — deCODE genetics (Nasdaq: DCGN) today announced the principal
results from its Phase IIa information - rich clinical trial ™ of DG031, the company's developmental compound which is being studied for the prevention of heart attack.
Results from Phase I and Phase II clinical trials were encouraging, with significant vision improvements reported for some patients.
The drug was approved based on efficacy and safety
results from a phase III trial presented earlier this year at the 2015 American Society of Clinical Oncology Annual Meeting.
Reykjavik, ICELAND, January 9, 2008 — deCODE genetics (Nasdaq: DCGN) today announced positive topline
results from its Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack.
February 21, 2006 deCODE genetics (Nasdaq: DCGN) today announced top - line
results from Phase I clinical studies of DG041, the company's developmental compound for the treatment of peripheral artery disease (PAD).
deCODE genetics (Nasdaq: DCGN) today announced positive top - line
results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack.
Following positive initial
results from Phase I safety trials evaluating direct administration of VRC01, an HIV - specific antibody that is able to neutralize a broad variety of HIV strains, the National Institute of Allergy and Infectious Diseases (NIAID) is preparing for a series of further studies to see if this broadly neutralizing antibody is effective in preventing transmission of HIV from mothers to their infants, as well as among high - risk adults.
The first - of - its - kind study found the dual treatments to be safe and elicit a clinical response in patients, according to new
results from a phase I trial to be presented at the AACR Annual Meeting 2015 on Sunday, April 19 (Abstract #CT137).
Early
results from a phase one study to establish the recommended dose of the OTX015 / MK -8628 BET inhibitor in hematologic malignancies reported the drug was tolerated; however, thrombocytopenia was a common toxic effect observed (Amorim et al., 2016).
This resource has: a) Ideas for investigating the Phase 10 Data (Ten Investigations using CensusAtSchool Phase 10 Data.doc), b) A spreadsheet containing the counts and percentages of
the results from Phase 10 up to February 2011 (CensusAtSchool Phase 10 summary spreadsheet.xls), c) A learners» worksheet to help them plan their investigation (CensusAtSchool Planning Worksheet.doc), d) An instruction sheet to use Pivot Tables in Excel (Pivot Tables in Excel.doc) e) A spreadsheet to be used with the Pivot Tables in Excel worksheet (Pivot Tables in Excel.xls).
IGNORE THESE FINDINGS AT YOUR PERIL: Project RED Announces Significant
Results from Phase III Research
«The Continual Intercomparison of Radiation Codes:
Results from Phase I.» Journal of Geophysical Research: Atmospheres, 117 (D6), 10.1029 / 2011jd016821.
That calculation is only as good as
your results from phase 2 trials.
Additional phases will commence as
results from phase One dictate.
Not exact matches
Alexion Reports First Quarter 2018
Results and Positive Topline Data
from ALXN1210
Phase 3 PNH Switch Study
Among the factors that could cause actual
results to differ materially are the following: (1) worldwide economic, political, and capital markets conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) the Company's credit ratings and its cost of capital; (3) competitive conditions and customer preferences; (4) foreign currency exchange rates and fluctuations in those rates; (5) the timing and market acceptance of new product offerings; (6) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (7) the impact of acquisitions, strategic alliances, divestitures, and other unusual events
resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (8) generating fewer productivity improvements than estimated; (9) unanticipated problems or delays with the
phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; and (11) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10 - K for the year ended Dec. 31, 2017, and any subsequent quarterly reports on Form 10 - Q (the «Reports»).
While young / first - steps content marketers can learn many things
from their more mature peers, one of the most striking — and encouraging — observations about those in the early
phase is that 71 % agree that their organization is focused more on building long - term relationships than on getting quick
results from content marketing.
Instead of working on the demand side, attention has turned to stimulating business through tax cuts, entrepreneurship and innovation while
phasing out excess capacity
resulting from the previous stimulus.
Interim
results showed that a majority of the 22 patients in the two
Phase 1/2 studies followed for two years or longer remained free
from transfusions.
The Study And The
Results The full data
from the
Phase III study,...
But the numbers are equally fun while being in the building
phase, and I get a lot of motivation
from tracking my own
results and seeing progress made by others.
George Budwell (Trevena): The clinical - stage biotech Trevena is set to release top - line
results from two
phase 3 studies (APOLLO - 1 and APOLLO - 2) for its lead drug candidate, oliceridine, in the first quarter of 2017.
For each
phase there corresponds a particular modification of the subjective aim, the «subjective end» of that
phase.30 The modification
results from the way antecedent feelings influence the subjective end, and that subjective end in turn influences successor feelings.
We can understand Russell's later cautious advocacy of an explicitly metaphysical position as in part
resulting from a consistent and continued commitment to, and application of, this method of logical construction, together with a dispassionate exploration of its full implications, rather than writing off this later
phase as entirely distinct and grossly inconsistent with the earlier
phases of Russell's career.
But the Darwinian stage showed that the cosmic process extends
from sidereal space to life on earth; with the
result that, in the present
phase, Man finds himself overtaken and borne on the whirlwind which his own science has discovered and, as it were, unloosed.
Those, however, who hope for unity through culture regard this diversity between cultures as a transitional
phase preceding the development of a world culture which will
result from cross-fertilization between national or racial cultures.
Accordingly, in the integrative
phase of the occasion it is merely reunited with the physical feeling
from which it was derived; the
resulting feeling is called a «physical purpose.»
Sonic's new policy will
result in the company
phasing - in the use of cage - free eggs as well as pork
from facilities that do not confine breeding pigs in gestation crates.
In this
phase it's important to assess the demands of your athletes» sport (movement patterns, speed, power and fatigue) when it comes to training the qualities that will
result in optimal performance transfer
from the gym.